Successfully steered a critical Phase III oncology trial for a novel mRNA therapeutic from site initiation to database lock in just 18 months, six months ahead of industry benchmarks, at Moderna. This accelerated timeline was achieved despite navigating a complex, multi-national regulatory landscape involving 15 countries and overseeing 80 clinical sites. The challenge involved integrating novel biomarker assays and managing a decentralized monitoring strategy, demanding meticulous planning and real-time data oversight to ensure patient safety and data integrity across diverse operational environments.
My expertise consistently drives operational efficiency and fiscal responsibility. I reduced overall trial expenditures by 12% ($4.5 million) on a Phase II infectious disease program by renegotiating CRO contracts and implementing a streamlined budget tracking system leveraging Oracle Clinical and eTMF. Furthermore, I developed and deployed a vendor oversight framework that improved site activation rates by 20% across a portfolio of three early-phase trials. I also proactively mitigated critical protocol deviations by 30% through enhanced investigator training and real-time data review processes, ensuring stringent adherence to GCP/ICH guidelines.
I am particularly drawn to Ascendant Biotherapeutics' pioneering work in targeted oncology therapies, especially your recent breakthroughs in KRAS inhibitor development. My strategic planning capabilities align perfectly with the complexity of advancing such innovative compounds through late-stage clinical development, where meticulous protocol design and robust risk mitigation are paramount. My strong program leadership skills would be invaluable in orchestrating the multi-disciplinary teams required to bring these transformative treatments to patients efficiently and compliantly.
My comprehensive experience in managing intricate clinical programs, coupled with a deep understanding of FDA and EMA regulations, positions me to make immediate and significant contributions to Ascendant Biotherapeutics. I am confident in my ability to enhance your clinical development pipeline and ensure successful trial execution. I look forward to discussing how my strategic vision and operational expertise can support your mission to deliver groundbreaking oncology solutions. Thank you for your consideration.
Best regards,
Patrick Sullivan